Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market
The regulator overhauled its approval process to accelerate the path to market for home-grown innovative drugs, state media reported on Wednesday.
The country elevated the pharmaceutical sector to a national economic growth engine in this year’s government work report for the first time. Last year, China approved 76 innovative drugs, up from 48 in 2024.
